New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 6, 2013
13:25 EDTANAC, ANAC, ANAC, VRX, VRX, VRXDeutsche Bank's specialty pharma analyst to hold a conference call
Specialty Pharmaceuticals Analyst Steinberg, along with Principal Investigator Max Weisfeld, D.P.M. Hamilton Foot Care Clinic Mid Atlantic Research Center for Health, discuss current and emerging treatments for onychomycosis (nail fungus) with a focus on Valeant's IDP-108 (NDA filed with the FDA) and Anacor's tavaborole (Phase 3) on an Analyst/Industry conference call to be held on February 8 at 2 pm.
News For ANAC;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 17, 2014
10:53 EDTVRXAckman says 'will take hard look' at Valeant shares after restrictions end
Subscribe for More Information
10:02 EDTANACOn The Fly: Analyst Initiation Summary
Subscribe for More Information
05:27 EDTANACAnacor initiated with a Neutral at Goldman
Goldman Sachs views Anacor Pharmaceuticals as an attractive dermatology name, but finds the stock fairly valued at current levels. The firm started shares with a Neutral rating and $36 price target.
December 9, 2014
09:31 EDTVRXZoetis drops after report of Valeant abandoning growth by acquisitions strategy
Subscribe for More Information
06:39 EDTVRXValeant to abandon growth by acquisitions strategy, Reuters says
Subscribe for More Information
December 8, 2014
07:29 EDTANACUBS to hold investor trip
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use